Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE3
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE1
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE2
Study of INCB053914 in Subjects With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2